JPMorgan Chase & Co. Sells 76,528 Shares of Caris Life Sciences, Inc. $CAI

JPMorgan Chase & Co. reduced its position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) by 8.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 858,105 shares of the company’s stock after selling 76,528 shares during the period. JPMorgan Chase & Co.’s holdings in Caris Life Sciences were worth $25,958,000 at the end of the most recent quarter.

Caris Life Sciences Trading Up 4.6%

CAI opened at $19.26 on Tuesday. Caris Life Sciences, Inc. has a 12 month low of $17.15 and a 12 month high of $42.50. The company has a debt-to-equity ratio of 0.66, a quick ratio of 7.35 and a current ratio of 7.85. The business has a 50-day moving average of $21.60. The stock has a market capitalization of $5.44 billion and a P/E ratio of -107.00.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.27. The company had revenue of $292.89 million for the quarter, compared to analysts’ expectations of $281.00 million. During the same quarter in the prior year, the company earned ($1.73) earnings per share. The company’s revenue was up 125.4% compared to the same quarter last year.

Analysts Set New Price Targets

Several research firms recently issued reports on CAI. Wall Street Zen raised Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. BTIG Research decreased their target price on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Canaccord Genuity Group lowered their price target on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a report on Friday, March 13th. Evercore set a $38.00 price target on Caris Life Sciences in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $31.50.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.